Literature DB >> 17554205

Prostate cancer mortality predictions for Ireland up to 2015.

Piaras O'Lorcain1, Harry Comber.   

Abstract

The objective of this analysis was to predict average world age-standardized mortality rates per person-years (100,000 person-years) and numbers of prostate cancer deaths in Ireland for the years 2005, 2010 and 2015. Poisson linear and log-linear regression models of Irish prostate cancer mortality data for the years 1950-2002 were used to predict trends for the whole population, for men aged 0-64 and 50-74 years. The prostate cancer world age-standardized mortality rate in 2015 is predicted to remain unchanged from the average recorded in 1998-2002, while, because of population growth, the number of deaths is predicted to increase. In persons under 65 years of age, the world age-standardized mortality rate is expected to increase, but the number of deaths in this age group is expected to nearly double between 2002 and 2015. Similarly, the world age-standardized mortality rate for men aged 50-74 years is predicted to rise with the number of deaths in this age group expected to increase sharply. The historical evidence predicts a small increase of age-adjusted prostate cancer mortality rates in Ireland and only in the age groups of 0-64 and 50-74 years in the next 10 years, along with a continuing marked increase in number of deaths due to demographic change.

Entities:  

Mesh:

Year:  2007        PMID: 17554205     DOI: 10.1097/01.cej.0000236248.63489.4c

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  3 in total

1.  Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.

Authors:  Lisa Yan; Diane M Da Silva; Bhavna Verma; Andrew Gray; Heike E Brand; Joseph G Skeate; Tania B Porras; Shreya Kanodia; W Martin Kast
Journal:  Prostate       Date:  2014-11-14       Impact factor: 4.104

2.  Novel predictive tools for Irish radical prostatectomy pathological outcomes: development and validation.

Authors:  D M Fanning; F Yue; J M Fitzpatrick; R W G Watson
Journal:  Ir J Med Sci       Date:  2009-07-14       Impact factor: 1.568

3.  Challenges in generating costs and utilisation rates associated with castration-resistant prostate cancer.

Authors:  Siobhan Bourke; Richéal Maria Burns; Caroline Gaynor
Journal:  J Mark Access Health Policy       Date:  2014-07-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.